Peripheral T-cell lymphomas (PTCLs) are biologically heterogeneous and have not been successfully correlated with specific T-cell subsets. We investigated PTCL, not otherwise specified (NOS), angioimmunoblastic T-cell lymphoma (AILT), and anaplastic large cell lymphoma (ALCL) cases for FoxP3 expression to determine a potential derivation from regulatory T (T reg ) cells. One PTCL-NOS case strongly expressed FoxP3 in the neoplastic T cells and showed unusual histomorphologic features with a dense infiltration of the lymph node by immunoblastic T cells and almost no reactive background infiltrate. The patient died shortly after diagnosis, suggesting that biologic properties of T reg cells may have contributed to the rapidly fatal clinical course. All remaining PTCL-NOS and AILT cases showed FoxP3 positivity only in the reactive infiltrate. Among ALCL cases, 4 of 6 ALK+ cases displayed weak and inhomogeneous FoxP3 expression in the tumor cells. FoxP3+ PTCL-NOS presumably derived from bona fide T reg cells occurs but seems rare in the Western population.
The World Health Organization (WHO) classification of malignant lymphoma relies on the concept of normal B-and T-cell counterparts. Although this concept has been successfully established in many subsets of B-cell lymphomas, it has proven difficult to adopt this strategy in the less frequent T-cell lymphomas. 1 By gene expression analyses, several subsets of effector T cells (T-helper 1, T-helper 2, and germinal center B-helper T cells), as well as memory subsets (central memory and effector memory), and cytotoxic T cells have been well defined on the molecular level. 2 Immunologically, most of these T-cell subsets are characterized by their interleukin (IL) production or by defined responses to stimulatory mechanisms. However, in tissue sections from routinely obtained and paraffin-embedded lymph node specimens, it is difficult to recognize these normal T-cell subsets because they have overlapping immunohistochemical features. In an attempt to relate T-cell lymphomas to their nonneoplastic counterpart, it was recently suggested that angioimmunoblastic T-cell lymphomas (AILTs) correlate with germinal center B-helper T cells based on their expression of CXCL13 and CD10. 3, 4 The idea of T cells that are able to regulate immune responses dates back to the 1970s when T cells were defined that were capable of inhibiting autoimmune reactions. Currently, such T cells are known as regulatory T (T reg ) cells. Based on mouse models, T reg cells are characterized by the expression of CD4 and CD25 and by the secretion of important effector cytokines such as IL-10 and transforming growth factor β, that can be produced under certain circumstances. 5 However, CD25-T reg cells also exist among humans and mice. [6] [7] [8] [9] [10] [11] [12] [13] T reg cells constitutively express CD45RO, 14 FAS, 15 CTLA-4, and an αβ T-cell receptor (TCR), 16 and, more recently, FoxP3 has been described as an important transcription factor that is essential for the differentiation of T cells into regulatory CD4+/CD25+ T cells. 17 Lack of functional FoxP3 leads to a human autoimmune syndrome called IPEX (immunodysregulation, polyendocrinopathy, enteropathy, X-linked). 18 Besides natural T reg cells that express FoxP3 constitutively, so-called adaptive/induced T reg cells have been described that express FoxP3 only after induction. [6] [7] [8] 10, 15, 17, 19, 20 In solid tumors, the occurrence of T reg cells among tumor-infiltrating lymphocytes has been proposed to facilitate invasive growth by suppression of the immune responses. 21, 22 Given that FoxP3 is a crucial transcription factor that is specifically expressed in T reg cells, [23] [24] [25] we screened 83 peripheral T-cell lymphomas (PTCLs) for this marker to determine if T reg cells may represent the normal counterpart of a subset of PTCL. We identified 1 PTCL, not otherwise specified (NOS) with strong and uniform FoxP3 expression, suggesting that it may be derived from natural T reg cells. Furthermore, we demonstrated that FoxP3 is expressed in an inhomogeneous manner in ex vivo tissue of anaplastic lymphoma kinase (ALK)+ anaplastic large cell lymphoma (ALCL), pointing to an induced mode of FoxP3 expression as a consequence of ALK deregulation, in concert with recently published data of ALK+ ALCL cell lines expressing FoxP3. 26 
Materials and Methods

Immunohistochemical Analysis
We studied the expression of FoxP3 (rabbit polyclonal, dilution 1:50; Abcam, Cambridge, England) in lymph node specimens from 83 cases of PTCL by conventional immunohistochemical analysis. All cases had been diagnosed according to the WHO classification and were characterized by using a broad panel of antibodies.
Of the study cases, 67 were paraffin-embedded material comprising 23 PTCL-NOS (9 of these were formerly diagnosed as T-immunoblastic non-Hodgkin lymphoma according to the Kiel classification), 16 AILT, 20 ALCL (14 ALK-and 6 ALK+), and 8 other types of T-cell lymphoma (2 cutaneous, 4 intestinal, 1 hepatosplenic, and 1 T/NK-cell lymphoma, nasal type). Because PTCLs contain numerous reactive T cells, we studied 16 frozen tumor samples from additional patients using double stains. These included 7 cases of AILT and 9 cases of PTCL-NOS that have been reported previously. 27 The 20 ALCL cases were further characterized for expression of CD4 (1F6, dilution 1:5; Loxo, Dossenheim, Germany), CD8 (C8/144B, dilution 1:20; DakoCytomation, Hamburg, Germany), CD30 (dilution 1:10; DakoCytomation), CD25 (2A3, dilution 1:10; Becton Dickinson Immunocytometry Systems, San Jose, CA), CD45RO (ACT-1, dilution 1:500; DakoCytomation), FAS (B-10, dilution 1:250; Santa Cruz, Santa Cruz, CA), and CTLA-4 (BNI3, dilution 1:200; BD Biosciences, San Diego, CA).
Immunohistochemical analysis was performed according to standard protocols. Following deparaffinization, tissue sections were heat-treated for 6 minutes at 121°C using targetretrieval solution, pH 6.1 (DakoCytomation) for the antibodies CD25, FAS, CTLA-4, and FoxP3. For ALK1, CD4, CD8, CD45RO, and CD30 staining, heat treatment in citrate buffer, pH 6.0, was applied.
In the 7 AILT and 9 PTCL-NOS cases with available frozen material, we studied the expression of FoxP3 (goat polyclonal, dilution 1:200; Abcam), CD4 (MT310, dilution 1:10; DakoCytomation), CD25 (ACT-1, dilution 1:2,000; DakoCytomation), CD45RO (UCHL1 FITC, dilution 1:10; Dianova, Hamburg, Germany), and FAS and CTLA-4 by fluorescence double stainings with the respective TCR V β antibody (Beckman Coulter, Marseille, France) recognizing the TCR V β segment that is rearranged and expressed by the neoplastic cells as previously shown. 28 Fluorescence images were evaluated by using confocal laser scanning microscopy (Leica TCS2, Leica, Bensheim, Germany).
Statistical Analysis
We compared FoxP3 expression between ALK+ and ALK-ALCL cases by using the χ 2 test. A P value less than .05 was considered statistically significant. Cluster analysis was performed to compare CD4, CD25, CD45RO, FAS, CTLA-4, and FoxP3 expression among ALCL cases.
Polymerase Chain Reaction for HTLV-1 Detection
The FoxP3+ PTCL-NOS was studied for a potential association with a human T-cell lymphotropic virus (HTLV)-1 infection by a polymerase chain reaction (PCR) that detects the presence of proviral HTLV-1 DNA in the tumor. Primary and nested primers were used according to Costa et al. 29 For this part of the study, 500 ng of DNA template, in a final volume of 25 µL, was amplified in a reaction mixture containing a final concentration of 0.2 µmol/L primer, 0.25 mmol/L deoxynucleoside triphosphates (Fermentas, St Leon-Rot, Germany), and 1× Taq polymerase buffer with 2 mmol/L of magnesium chloride and 0.65 U of Taq polymerase (Taq DNA polymerase, recombinant, Invitrogen, Karlsruhe, Germany). PCRs were run for 35 cycles in a thermocycler (Mastercycler gradient, Eppendorf, Wesseling-Berzdorf, Germany). After a 5-minute denaturation at 94°C, each cycle consisted of 30 seconds at 94°C, 30 seconds at an annealing temperature of 60°C, and 1 minute 30 seconds at 72°C followed by a final extension step of 7 minutes at 72°C. PCR products of the expected size were separated on an EtBr-stained agarose gel and purified (JETSORB gel extraction kit, Genomed, Loehne, Germany). Aliquots of 7 µL were used for sequencing analysis with 1 µmol/L of the respective primer and 2 µL of BigDye Terminator v3.1 Cycle Sequencing Reaction Mix (Applied Biosystems, Foster City, CA) in a final volume of 10 µL. Samples were analyzed in a 3130xl Genetic Analyzer (Applied Biosystems).
Ethics Approval
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Results
AILT and Other Subtypes of PTCL
Among the 83 PTCL cases studied, the neoplastic T cells in all 23 AILT cases were completely FoxP3-. FoxP3 positivity could only be detected in a few cells of the reactive infiltrate (data not shown). Likewise, the neoplastic cells of the 8 cases belonging to other T-cell lymphoma subtypes (cutaneous, intestinal, and hepatosplenic T-cell lymphoma and T/NK-cell lymphoma, nasal type) were also completely negative for FoxP3 expression.
PTCL, Not Otherwise Specified
Among 14 PTCL-NOS cases primarily studied, only 1 case strongly and uniformly expressed FoxP3. All remaining 13 cases were negative. The results of the single stains in paraffin-embedded tissue were in agreement with those obtained in frozen specimens from 9 patients by fluorescence double staining and, thus, confirmed the presence of only a few FoxP3+ reactive T cells, whereas the neoplastic clone was FoxP3-.
Because the only case that showed strong FoxP3 expression in the neoplastic cells corresponded to the immunoblastic variant of PTCL-NOS (according to the Kiel classification), we studied 9 additional PTCL-NOS cases showing immunoblastic morphologic features. However, in all of these cases, the neoplastic cells were also negative for FoxP3.
Histologically, the FoxP3+ tumor showed a diffuse growth pattern of variably medium-sized or large atypical T cells with convoluted nuclei and mostly prominent nucleoli zImage 1Az. It is interesting that there was only a minor background infiltrate, which is rather unusual among PTCL cases zImage 1Bz. Immunohistochemically, the tumor cells expressed an αβ TCR (V β 5s1) and CD4, CD45RO, FAS, and CTLA-4 zTable 1z and were negative for CD30 (data not shown). In contrast, CD25 was undetectable on the immunohistochemical level. There was no evidence of an HTLV-1 association because HTLV-1 proviral DNA was not amplifiable by PCR. In contrast, a lymph node from a patient with known HTLV-1 infection that was used as a positive control sample displayed HTLV-1-specific PCR products as confirmed by sequence analysis (data not shown).
The FoxP3+ tumor occurred in a 59-year-old man with pathologically enlarged cervical, mediastinal, axillary, intra-abdominal, retroperitoneal, and inguinal lymph nodes who was diagnosed with a T-immunoblastic non-Hodgkin lymphoma according to the Kiel classification at that time, which falls into the category of PTCL-NOS in the current WHO classification. At diagnosis, the patient was in a good physical condition and had stage IV disease, no evidence of involvement of extranodal sites, and an elevated lactate dehydrogenase value. He received chemotherapy according to the CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisolone) protocol. Five days later, his general condition deteriorated and, during the chemotherapy-induced neutropenia phase, he had repeated infections. One month after the initial diagnosis, the patient died.
Anaplastic Large Cell Lymphoma
We studied FoxP3 expression in 20 lymph node specimens from patients with ALCL, including ALK+ and ALKtumors. We found expression of FoxP3 in 4 of 6 ALK+ ALCL and 1 of 14 ALK-ALCL cases. However, in contrast with the PTCL-NOS case described, FoxP3 expression was not strong and uniform, but rather relatively weak and variable among the tumor cells zImage 2z. On average, only 20% to 30% of the morphologically recognizable tumor cells were stained with FoxP3. The difference in FoxP3 expression between ALK1+ and ALK1-ALCL was statistically significant. In comparing the expression of other markers related to the T reg cell phenotype, which were, except CD25, also expressed in the FoxP3+ PTCL-NOS case (CD4, CD25, CD45RO, FAS, and CTLA-4) zTable 2z, we performed a cluster analysis of the immunohistochemical data obtained in the ALCL cases. 
AILT, angioimmunoblastic T-cell lymphoma; PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified; +, positive; -, negative; (+), weak positivity.
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zImage 2z A, Anaplastic lymphoma kinase (ALK)+ anaplastic large cell lymphoma (ALCL) (Giemsa, ×200). B, ALK+ ALCL (FoxP3 staining, ×200).
In contrast with the homogeneous staining pattern of FoxP3, FAS, and CTLA-4, a heterogeneous staining pattern was detected for CD4, CD25, and CD45RO among ALK+ and ALK-ALCL cases, indicating that ALCLs do not show the complete phenotype of T reg cells. Among the 11 CD4-ALCLs (Table 2) , only 1 ALK+ ALCL (FoxP3-) expressed CD8 (data not shown).
Discussion
In this study, we tried to identify nodal PTCLs that may be derived from T reg cells. Surprisingly, we found only 1 FoxP3+ PTCL-NOS among 63 PTCL cases, excluding ALCL cases. To the best of our knowledge, T reg cell phenotypes have not been described in nodal PTCL in Western countries. We therefore conclude that the derivation of nodal PTCL from T reg cells occurs but is a rare event, at least within the white population.
It is tempting to speculate that some of the morphologic and clinical features of the case described herein may be explained by the retained regulatory function of the tumor cells. First, the tumor showed a growth pattern that is rare in PTCL-NOS because only a few tumor-infiltrating reactive T or B cells could be observed within the tumor cell infiltrate, and the growth pattern was almost cohesive. This paucity of reactive background cells may be caused by the immunosuppressive function of the tumor cells. Second, the regulatory T-cell function might have significantly suppressed antitumoral immunity, thereby contributing to the rapid progression of disease and poor clinical course of the patient. Although the majority of patients with PTCL-NOS have a poor clinical outcome, the rapid and fatal progression seen in the FoxP3+ case described herein differs from the typical clinical course of PTCL-NOS in general. Thus, FoxP3-expression and the associated regulatory phenotype might be an adverse biologic and clinical factor in rare PTCL cases that contributes to the aggressiveness of the tumor.
Particularly, the strong FoxP3 expression in our case suggests that this tumor might have arisen from a natural T reg cell, even though the tumor cells were negative for CD25, which is a phenotype that has been described among T reg cells in humans and mice. [6] [7] [8] [9] [10] [11] [12] [13] A subgroup of CCR4+ PTCL-NOS was previously associated with T reg cells by a Japanese group because these tumor samples expressed FoxP3 at elevated levels as measured by quantitative real-time PCR. However, this study did not investigate whether FoxP3 was coexpressed in the tumor cells or derived from accompanying nonneoplastic T reg cells in the reactive infiltrate. 30 Whereas a T reg cell phenotype has not been convincingly demonstrated in nodal PTCL, subsets of extranodal PTCL have been suggested to be derived from T reg cells. In 5 studies, cases of HTLV-1-associated adult T-cell leukemia/lymphoma (ATLL) have been shown to express FoxP3 and were, therefore, considered to be derived from T reg cells. [31] [32] [33] [34] [35] It is interesting that these lymphomas are also characterized by a poor prognosis. 1, 36, 37 Whereas purified tumor cells from peripheral blood mononuclear cells (PBMCs) or lymph nodes of patients with ATLL show in 50% to 100% of cases elevated FoxP3 expression by real-time PCR and immunohistochemical analysis, 1 study revealed widely varying results in Western blot analysis. 33 In addition to ATLL, 1 of 3 cases of T-cell prolymphocytic 38 This finding may be explained by the finding of Berger and colleagues, 39 who were able to demonstrate that a regulatory T-cell phenotype can be induced in cutaneous T-cell lymphoma by cultivating purified PBMCs with dendritic cells loaded with apoptotic material. In our case, we demonstrated by PCR that the regulatory phenotype was not associated with an HTLV-1 infection.
In contrast with the aforementioned entities, the mode of FoxP3 induction in ALK+ ALCL seems to be different. Only a subset of tumor cells in ALK+ ALCL expressed FoxP3, and the level of expression varied among tumor cells, pointing to an intricate mechanism of FoxP3 regulation. Recent data suggest that FoxP3 may be up-regulated as a consequence of ALK deregulation in ALCL, as has been shown in ALK+ ALCL cell lines. In particular, Kasprzycka et al 26 demonstrated elevated FoxP3 expression in 4 of 4 ALK+ ALCL cell lines as evidenced by real-time quantitative PCR, whereas by Western blot analysis, 1 of the cell lines showed strong and 3 showed weak FoxP3 expression. The same authors provided evidence that the regulatory T-cell phenotype was induced by ALK, as lymphoid cells transfected with NPM/ALK induced the T reg cell phenotype, and inhibition of NPM/ALK function in ALK+ cell lines suppressed the T reg cell phenotype. Furthermore, the authors identified STAT3, which is activated by NPM/ALK, as an effector of the T reg cell phenotype induction by activating IL-10, transforming growth factor β, and FoxP3 expression. In line with these results, we found significantly different FoxP3 expression between ALK+ and ALK-ALCLs. Only 1 of 14 ALK− ALCLs expressed FoxP3. Considering these findings together, the induced FoxP3 expression in ALK+ ALCLs seems to be an epiphenomenon following aberrant ALK overexpression without a real T reg cell derivation of the tumor cells. This conclusion may be additionally supported by our results that show a lack of other characteristics of T reg cells, as CD4, CD25, CD45RO, FAS, and, especially, CTLA-4 are not constantly coexpressed with FoxP3 (Table 2) .
We describe a putatively natural T reg cell phenotype in a case of a nodal PTCL-NOS. Some of the morphologic and clinical peculiarities of this case may be explained by the retained T reg cell function in the neoplastic T-cell clone. Thus, although rare, a T reg cell phenotype may represent an adverse risk factor in PTCL-NOS.
